I-Mab Expands Next-Gen Novel Oncology Portfolio

I-Mab, a clinical stage biopharmaceutical company developing novel biologics, signed two new collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company. The alliances provide I-Mab with access to transformative technologies to discover and develop oncology therapeutics. I-Mab will be developing anti-cancer antibody therapeutics through Immorna's self-replicating mRNA platform.

Through a strategic collaboration, I-Mab will work with neoX Biotech for up to 10 novel biologics programs using neoX's artificial intelligence algorithm. I-Mab also has existing collaboration agreements with Complix for cell-penetrating antibody platform and Affinity for masking antibody platform, expanding its pipeline of next generation antibody assets enabled by transformative technologies.

"Since the launch of our discovery initiative earlier this year, we have identified transformative technologies that can enable us to rapidly expand the emerging portfolio of next generation novel antibody assets to sustain our innovative immuno-oncology pipeline," said Dr. Taylor Guo, Chief Scientific Officer of I-Mab. "The immense success of COVID-19 mRNA vaccines exemplifies that mRNA-based drugs have finally established themselves as transformative medicines. And channeling the power of AI into drug discovery holds great promise from unlocking novel targets and modalities to accelerating all aspects of R&D. By embracing these technologies, we have again demonstrated our commitment in executing against our long-term innovation strategy."

Both partner companies will receive undisclosed upfront and/or milestone payments under the collaboration agreements.